Skip to main contentrtttttt Skip to main content
Integrative Psychiatry

Psychedelics and Mindfulness

By August 14, 2024No Comments

Both psychedelic use and mindfulness practices have been used for thousands of years across the world, often for spiritual purposes. While psychedelics are currently gaining therapeutic influence in the United States, mindfulness is still largely considered an elusive mental health tool. 

So what is mindfulness? Mindfulness is characterized by awareness of and nonjudgement toward present moment feelings, thoughts, and bodily sensations; in other words, mindfulness is a connection to the self that tracks internal experiences, particularly emotional attachments. Anecdotal reports suggest that psychedelic use might be supportive for cultivating such states of being. Newer research hypothesizes that psychedelics and mindfulness are synergistic in their effects, impacting the experience of each other. 

Both psychedelics and mindfulness practices can influence perception, cognition, and emotional regulation. For example, psychedelics may produce states of transcendence, tapping into spiritual realms beyond the body and mind. Sometimes a temporary step outside of the self makes it easier to notice and observe what is happening within the self, such as physical senses (sights, smells, muscle tension/relaxation, etc), intuitions, and emotions. In this way, psychedelics may also support re-engagement with the body (see blog on psychedelics and embodied cognition here) and reorganization of self identities (see blog on psychedelics and the self here), similar to reported effects of meditation and yoga.

Psychedelic therapy and mindfulness-based therapies also have direct and overlapping influences on neuroscience and physiology. Both therapeutic approaches have effects on the default mode network in the brain, the circuit that is most active during self-directed thought and rumination. Psychedelics and mindfulness exercises tend to reduce activity in this brain region, which may be related to letting go of a fixed sense of self. Psychedelic administration and meditation have also been independently shown to impact the immune system, lowering inflammatory markers and helping the body adapt to stressors.

Psychedelics Support Mindfulness

Psychedelics have been called a “gateway” to mindfulness because they facilitate a state of heightened awareness and openness. Some studies have found that psychedelic use (regardless of whether or not it was “therapeutic” or conducted with a facilitator present) is naturally associated with increased engagement with mindfulness meditation. This might be due to overlapping psychological impacts. For example, psychedelics might alter a person’s sense of time and space, allowing for a deep immersion in the now. Another common psychedelic experience is the dissolution of the ego, which helps reduce the rigidity of personal stories and habitual thought patterns, leading to a de-attachment of judgements. Soothing a protective or reactive inner dialogue may open individuals to new ways of thinking, perceiving, and behaving in the world; in this way, benefits of psychedelic-enhanced mindfulness include increased psychological and cognitive flexibility.

Psychedelic dosing sessions can bring hidden, resisted, or suppressed emotions to the surface; psychedelic-assisted therapy (PAT) provides an opportunity for clients to confront and integrate such feelings in a safe, attentive, and therapeutic setting. The concept of “non-avoidance” offers that working through challenging experiences or content that arises during a psychedelic dosing session might actually confer therapeutic benefit, when handled in a safe container. Clinical trials have documented shifts in participant narrative attitudes about traumas, coping mechanisms, and identities following PAT protocols, leading to posttraumatic growth (see blog on posttraumatic growth here). By experiencing and accepting emotions that arise, individuals can develop greater resilience and self-awareness.

Psychedelic-assisted therapy training, such as IPI’s Psychedelic Assisted Psychotherapy Training (PAPT), emphasizes the importance of providing a calm, non-judgemental abiding presence, even when supporting a client through difficult experiences, suggesting that mindfulness is already a part of PAT best practices. Integrating insights from a psychedelic journey is also a vital component of PAT; mindfulness-based frameworks are often incorporated to help clients make sense of and conceptualize different parts of the experience. At this point, therapists and clients work together to encourage mindfulness in daily habits moving forward. 

Conclusion

In scientific literature, the relationship between psychedelic use and mindfulness is still largely undescribed, yet there are intriguing implications for their potential synergistic effects. Continuing the pursuit of understanding how these modalities influence wellbeing provides deeper insight into existential questions of consciousness, existence, and what it means to be human.

Sara Reed, MS, LMFT

Sara Reed is a Licensed Marriage and Family Therapist and CEO of Mind’s iHealth Solutions, a digital health company that provides evidence based and culturally responsible mental health services for underserved groups. As a mental health futurist and clinical researcher, Sara examines the ways culture informs the way we diagnose and treat mental illness. Sara’s prior research work includes participation as a study therapist in psychedelic therapy research at Yale University and the University of Connecticut’s Health Center. Sara was the first Black therapist to provide MDMA-assisted psychotherapy in a clinical trial and continues to engage in ongoing advocacy work around health equity in psychedelic medicine.

https://psychiatryinstitute.com/wp-content/uploads/2019/11/Jeffrey-Guss.png

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy and the treatment of substance use disorders. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psychedelic-assisted psychotherapy in the treatment of cancer-related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psychedelic-Assisted therapy in the treatment of Alcoholism, a collaborator with Yale University’s study on psychedelic-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS (Multidisciplinary Association for Psychedelic Studies) study on treatment of Post Traumatic Stress Disorder with Psychedelic-Assisted Psychotherapy. 

Dr. Guss is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He has published (with Elizabeth Nielson, PhD) a paper on “the influence of therapists’ first had experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training” in The Journal of Psychedelic Studies, August, 2018. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies and Supervisor in NYU’s Fellowship in Addiction Psychiatry. 

Dr. Guss maintains a private practice in New York City.

Will Van Derveer, MD

Will Van Derveer, MD is Co-Founder of Integrative Psychiatry Institute and Integrative Psychiatry Centers. Dr. Van Derveer was co-investigator on a phase 2 MAPS study of Psychedelic-assisted psychotherapy for treatment-resistant PTSD, and co-authored the publication of this study in 2018. He has also provided Psychedelic-assisted psychotherapy in two MAPS training studies. An active provider of KAP at his clinic in Boulder, CO, he has been teaching others KAP therapy for several years. Dr. Van Derveer contributed a chapter on mescaline in the 2021 "Handbook of Medical Hallucinogens" (edited by Charles Grob and Jim Grigsby). He is co-host of the Higher Practice Podcast.

Dr. Van Derveer regards unresolved emotional trauma as the most significant under-recognized root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass.


Scott has been a student of consciousness since his honors thesis on that topic at the University of Arizona in the 1970s under the tutelage of Dr. Andrew Weil. Following medical school, Scott studied Jungian therapy and acupuncture while working as a primary care physician in a rural area for four years. Psychedelic-assisted psychotherapy became a facet of his practice before this medicine was scheduled in 1985. He then completed a psychiatry residency at Columbia program in New York. Scott studied cross-cultural psychiatry and completed a child/adolescent psychiatry fellowship at the University of New Mexico.

In 2010 he founded Wholeness Center in Fort Collins. This innovative clinic provides cross-disciplinary evaluation and care for all mental health concerns. Scott serves as a site Principal Investigator and therapist for the Phase III trial of psychedelic-assisted psychotherapy for PTSD sponsored by (MAPS). He has also published numerous articles about his research on (CBD) in mental health. Currently, Scott works extensively with psychedelic-assisted-psychotherapy. He lectures all over the world to professional groups interested in a deeper look at mental health issues, safer tools, and a paradigm-shifting perspective about transformative care.

Will Van Derveer, MD is co-founder of Integrative Psychiatry Institute (IPI), along with friend and colleague Keith Kurlander, MA. He co-created IPI as an expression of what he stands for. First, that anyone can heal, and second that we medical providers must embrace our own healing journeys in order to fully command our potency as healers.

Dr. Van Derveer spent the last 20 years innovating and testing a comprehensive approach to addressing psychiatric challenges which transcends the conventional model he learned in medical school at Vanderbilt University and residency at University of Colorado, while deeply engaging his own healing path.

He founded the Integrative Psychiatric Healing Center in in 2001 in Boulder, CO, where he currently practices. Dr. Van Derveer regards unresolved emotional trauma as the most significant root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass. In addition to his clinical work and teaching, he was co-investigator in 2016 a Phase II randomized clinical trial, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). He continues to support this protocol, now in a Phase III clinical trial under break-through designation by FDA.

Dr. Van Derveer is a diplomate of the American Board of Integrative and Holistic Medicine (ABoIHM) since 2013, and he was board certified in the first wave of diplomates of the new American Board of Integrative Medicine (ABIM) in 2016.